Year Founded
2016
Ownership
Private
Employees
~165
Therapeutic Areas
OncologyDermatology
Stage
Commercial
Modalities
Antibody-based immunotherapySmall molecule

TerSera Therapeutics General Information

Commercial stage company with approved products including MARGENZA (margetuximab-cmkb) for HER2+ breast cancer and intravenous cetirizine for acute urticaria

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Deerfield, Illinois
United States

Drug Pipeline

margetuximab
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to TerSera Therapeutics's pipeline data

Book a demo

Key Partnerships

MacroGenics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

TerSera Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view TerSera Therapeutics's complete valuation and funding history, request access »